Comparison of limus-eluting stent with paclitaxel-eluting stent for patients with coronary small vessel disease:a systematic review and meta-analysis

Abstract

To compare the efficacy of limus-eluting stent (LES) with paclitaxel-eluting stent (PES) for patients with coronary small vessel disease. The studies of LES and PES used for patients with coronary small vessel disease were searched in PubMed, Web of Science, ClinicalTrials, SinoMed, CNKI, Wanfang data and CQVIP. The relative risk (RR) estimates with 95% confidence intervals and other statistical variables were calculated with Stata 14.0, and the meta analysis was performed with RevMan 5.2. Eight studies involving 4738 patients were included in the meta-analysis. Compared with PES, LES implantation was associated with significant reduction in major adverse cardiovascular events (RR=0.64, 95% CI:0.53-0.77, Z=4.59, P<0.01), myocardial infarction (RR=0.61, 95% CI:0.45-0.82; Z=3.24, P<0.01), stent thrombosis (RR=0.22, 95% CI:0.13-0.37, Z=5.71, P<0.01), and target lesion revascularization (RR=0.56, 95% CI:0.44-0.71, Z=4.72, P<0.01), while no difference was observed in cardiac death (RR=1.08, 95% CI:0.62-1.88, Z=0.26, P>0.05) and target vessel revascularization(RR=0.80, 95% CI:0.45-1.44, Z=0.74, P>0.05). LES has better efficacy than PES for patients with coronary small vessel disease, which may be the preferred stents for these patients.